世界のノイラミニダーゼ阻害薬市場2020-2025:オセルタミビル、ザナミビル、ペラミビル、ラニナミビル

LP Informationが発行した調査報告書(LPI20OC2714)
◆英語タイトル:Global Neuraminidase Inhibitors Drug Market Growth (Status and Outlook) 2020-2025
◆商品コード:LPI20OC2714
◆発行会社(リサーチ会社):LP Information
◆発行日:2020年10月5日(※2024年版があります。お問い合わせください。)
◆ページ数:118
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:Pharma & Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

「ノイラミニダーゼ阻害薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、オセルタミビル、ザナミビル、ペラミビル、ラニナミビルなど、用途別には、病院薬局、小売薬局、オンライン薬局、その他などに区分してまとめた調査レポートです。ノイラミニダーゼ阻害薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・ノイラミニダーゼ阻害薬の世界市場概要(サマリー)
・ノイラミニダーゼ阻害薬の企業別販売量・売上
・ノイラミニダーゼ阻害薬の企業別市場シェア
・ノイラミニダーゼ阻害薬の世界市場規模 2015年-2020年:種類別(オセルタミビル、ザナミビル、ペラミビル、ラニナミビル)
・ノイラミニダーゼ阻害薬の世界市場規模 2015年-2020年:用途別(病院薬局、小売薬局、オンライン薬局、その他)
・ノイラミニダーゼ阻害薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・ノイラミニダーゼ阻害薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・ノイラミニダーゼ阻害薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・ノイラミニダーゼ阻害薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・ノイラミニダーゼ阻害薬市場の成長要因・課題・動向
・ノイラミニダーゼ阻害薬の世界市場予測 2021年-2025年
・ノイラミニダーゼ阻害薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・ノイラミニダーゼ阻害薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・ノイラミニダーゼ阻害薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・ノイラミニダーゼ阻害薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・ノイラミニダーゼ阻害薬の世界市場予測:種類別(オセルタミビル、ザナミビル、ペラミビル、ラニナミビル)
・ノイラミニダーゼ阻害薬の世界市場予測:用途別(病院薬局、小売薬局、オンライン薬局、その他)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Neuraminidase Inhibitors Drug market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Neuraminidase Inhibitors Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuraminidase Inhibitors Drug market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Neuraminidase Inhibitors Drug, covering the supply chain analysis, impact assessment to the Neuraminidase Inhibitors Drug market size growth rate in several scenarios, and the measures to be undertaken by Neuraminidase Inhibitors Drug companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.
Oseltamivir
Zanamivir
Peramivir
Laninamivir

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
GSK
Daiichi Sankyo
Gilead Sciences

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Neuraminidase Inhibitors Drug market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Neuraminidase Inhibitors Drug market by identifying its various subsegments.
Focuses on the key global Neuraminidase Inhibitors Drug players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Neuraminidase Inhibitors Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Neuraminidase Inhibitors Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuraminidase Inhibitors Drug Market Size 2015-2025
2.1.2 Neuraminidase Inhibitors Drug Market Size CAGR by Region
2.2 Neuraminidase Inhibitors Drug Segment by Type
2.2.1 Oseltamivir
2.2.2 Oseltamivir
2.2.3 Peramivir
2.2.4 Laninamivir
2.3 Neuraminidase Inhibitors Drug Market Size by Type
2.3.1 Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)
2.3.2 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (2015-2020)
2.4 Neuraminidase Inhibitors Drug Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.4.4 Others
2.5 Neuraminidase Inhibitors Drug Market Size by Application
2.5.1 Global Neuraminidase Inhibitors Drug Market Size Market Share by Application (2015-2020)
2.5.2 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application (2015-2020)

3 Global Neuraminidase Inhibitors Drug by Players
3.1 Global Neuraminidase Inhibitors Drug Market Size Market Share by Players
3.1.1 Global Neuraminidase Inhibitors Drug Market Size by Players (2018-2020)
3.1.2 Global Neuraminidase Inhibitors Drug Market Size Market Share by Players (2018-2020)
3.2 Global Neuraminidase Inhibitors Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Neuraminidase Inhibitors Drug by Regions
4.1 Neuraminidase Inhibitors Drug Market Size by Regions
4.2 Americas Neuraminidase Inhibitors Drug Market Size Growth
4.3 APAC Neuraminidase Inhibitors Drug Market Size Growth
4.4 Europe Neuraminidase Inhibitors Drug Market Size Growth
4.5 Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth

5 Americas
5.1 Americas Neuraminidase Inhibitors Drug Market Size by Countries
5.2 Americas Neuraminidase Inhibitors Drug Market Size by Type
5.3 Americas Neuraminidase Inhibitors Drug Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Neuraminidase Inhibitors Drug Market Size by Regions
6.2 APAC Neuraminidase Inhibitors Drug Market Size by Type
6.3 APAC Neuraminidase Inhibitors Drug Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Neuraminidase Inhibitors Drug by Countries
7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type
7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Neuraminidase Inhibitors Drug by Countries
8.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type
8.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Neuraminidase Inhibitors Drug Market Forecast
10.1 Global Neuraminidase Inhibitors Drug Market Size Forecast (2021-2025)
10.2 Global Neuraminidase Inhibitors Drug Forecast by Regions
10.2.1 Global Neuraminidase Inhibitors Drug Forecast by Regions (2021-2025)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Neuraminidase Inhibitors Drug Forecast by Type
10.8 Global Neuraminidase Inhibitors Drug Forecast by Application

11 Key Players Analysis
11.1 Roche
11.1.1 Company Details
11.1.2 Neuraminidase Inhibitors Drug Product Offered
11.1.3 Roche Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)
11.1.4 Main Business Overview
11.1.5 Roche News
11.2 GSK
11.2.1 Company Details
11.2.2 Neuraminidase Inhibitors Drug Product Offered
11.2.3 GSK Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)
11.2.4 Main Business Overview
11.2.5 GSK News
11.3 Daiichi Sankyo
11.3.1 Company Details
11.3.2 Neuraminidase Inhibitors Drug Product Offered
11.3.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)
11.3.4 Main Business Overview
11.3.5 Daiichi Sankyo News
11.4 Gilead Sciences
11.4.1 Company Details
11.4.2 Neuraminidase Inhibitors Drug Product Offered
11.4.3 Gilead Sciences Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)
11.4.4 Main Business Overview
11.4.5 Gilead Sciences News

12 Research Findings and Conclusion

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のノイラミニダーゼ阻害薬市場2020-2025:オセルタミビル、ザナミビル、ペラミビル、ラニナミビル(Global Neuraminidase Inhibitors Drug Market Growth (Status and Outlook) 2020-2025)]についてメールでお問い合わせはこちらでお願いします。